Vincristine News and Research

RSS

Vincristine is the active ingredient in a drug used to treat acute leukemia. It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. Vincristine is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division. It is a type of vinca alkaloid and a type of antimitotic agent.

Novel treatment strategy shows promise against common liver cancer in children

Hepatoblastoma (HB) is the most common liver cancer in children. Researchers and physicians in the field are concerned because in the last decade HB has been rising rapidly worldwide and has seen the most rapid increase among all pediatric solid tumors.

20 Feb 2024

A novel pharmacology modeling approach to monitor acute lymphoblastic leukemia treatment

This research paper published in Scientific Reports developed pharmacokinetic (PK) pharmacodynamic (PD) models of maintenance therapy for childhood acute lymphoblastic leukemia (ALL).

26 Jul 2023

Exploring remdesivir resistance in COVID-19-infected transplant recipients

In a new study, researchers assessed the remdesivir resistance developed in coronavirus disease 2019 (COVID-19)-infected transplant recipients.

29 Sep 2022

The risk of adverse reactions when herbal medications are taken with cancer drugs

A new study discusses phytovigilance initiatives based on the real-world use of herbal drugs in cancer along with conventional chemotherapy.

24 Aug 2022

Best available chemotherapy for HIV-related Kaposi sarcoma would save lives and be cost-effective in Africa

Although antiretroviral therapy has markedly improved survival in people with AIDS-associated Kaposi sarcoma (a type of cancer caused by a virus), the condition is still a life-threatening problem in low- and middle-income countries.

15 Jul 2022

Ibrutinib plus standard chemotherapy effective in younger patients with diffuse large B-cell lymphoma

Younger patients with specific genetic subtypes of non-GCB DLBCL, called MCD and N1, had an exceptional response to the treatment combination.

5 Nov 2021

Sunitinib extends progression-free survival in patients with rare neuroendocrine tumor, study shows

The first randomized study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months.

20 Sep 2021

Younger children more vulnerable to chemotherapy-related hearing loss, study finds

A chemotherapy drug known to cause hearing loss in children is more likely to do so the earlier in life children receive it, new UBC research has found.

7 Sep 2021

Chemotherapy drug can cause permanent hearing loss in young children with cancer

The chemotherapy drug cisplatin is an effective cancer treatment for many children with cancer, but unfortunately it can cause permanent hearing loss.

7 Sep 2021

International collaboration aims to develop better therapy for childhood acute lymphoblastic leukemia

Scientists at St. Jude Children's Research Hospital are working with colleagues in China to develop better therapy for childhood acute lymphoblastic leukemia (ALL).

27 Jul 2021

Chemotherapy drugs can induce mutations that lead to relapse in pediatric ALL patients

Chemotherapy has helped make acute lymphoblastic leukemia (ALL) one of the most survivable childhood cancers.

22 Jul 2021

Research shines new light on deadly medulloblastoma metastases

With advances in medical science driving progress against childhood brain tumors, today three out of four young patients survive at least five years beyond diagnosis. However, the outcomes look grim when malignant cells spread, or metastasize.

29 Jun 2021

Kinase inhibitors could provide an effective way to treat high-risk leukaemia

Australian scientists have found what could prove to be a new and effective way to treat a particularly aggressive blood cancer in children.

29 May 2021

Targeted therapy achieves excellent outcomes, reduces side effects in high-risk Hodgkin lymphoma

Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma.

8 Apr 2021

Discovery may help cancer patients to avoid chemotherapy's debilitating side effects

A discovery by University of Queensland pain researchers may allow some future cancer patients, including children with leukemia, to avoid their chemotherapy's worst and most debilitating side effects.

15 Mar 2021

Review helps understand the mechanisms of R-CHOP resistance in diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer of lymphocytes, and a large proportion of patients are either unresponsive or develop resistance towards R-CHOP—the standard treatment regimen.

8 Mar 2021

Study characterizes cisplatin-induced hearing loss in pediatric cancer patients

Cisplatin is one of the most effective chemotherapy agents, used in just under half of pediatric cancer cases.

13 Feb 2021

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).

7 Dec 2020

Severe lymphatic disorder reversed through genetic sequencing and targeted treatment

Through genetic sequencing and targeted treatment, researchers from Children's Hospital of Philadelphia have resolved a severe lymphatic disorder in a young woman with kaposiform lymphangiomatosis (KLA), a complex and rare disorder that causes lymphatic vessels around the heart and lung to leak fluid, causing breathing difficulties, infections, and often death.

5 Oct 2020

Adjuvant chemotherapy can improve overall survival in patients with high-risk, low-grade glioma

A practice-changing study, NRG Oncology clinical trial NRG-RTOG 9802, has demonstrated, for the first time, a survival benefit of adjuvant chemotherapy following radiotherapy over radiotherapy alone in certain subgroups of patients with high-risk, low-grade glioma (WHO classification: LGG, grade II), a type of brain tumor that originates from glial cells.

1 Sep 2020